Picture Berlin Partner BIO 2024 International Convention San Diego 650x100px

Document › Details

Nabriva Therapeutics plc. (11/6/18). "Press Release: Nabriva Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights". Dublin.

	Organisation	Nabriva Therapeutics plc (Nasdaq: NBRV)
	Group	Nabriva (Group)
	Organisation 2	Zavante Therapeutics Inc.
	Group	Nabriva (Group)
	Product	lefamulin (BC-3781)
	Product 2	Contepo™ (fosfomycin for injection, previously ZTI-01 and ZOLYD)
	Index term	Zavante Therapeutics–Nabriva: investment, 201807 acquisition upfront 8.2m Nabriva ordinary shares (=19.9% shareholding) + $97.5m milestones
	Person	Schroeder, Ted (Nabriva 201807– CEO before Zavante Therapeutics + Cadence Pharmaceuticals + Élan)
	Person 2	Garrett, Dave (Nabriva 201709 Investor Relations)

Original document
accessed by [iito] on 2018-12-23

Record changed: 2023-06-05

Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

More documents for Nabriva (Group)

[1] Nabriva Therapeutics plc. (2/26/21). "Press Release: Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer". Dublin & King of Prussia, PA....
[2] Nabriva Therapeutics plc. (12/20/19). "Press Release: Nabriva Therapeutics Announces $20 Million Registered Direct Offering". Dublin & King of Prussia, PA....
[3] Nabriva Therapeutics plc. (12/20/19). "Press Release: Nabriva Therapeutics Resubmits New Drug Application for Intravenous Contepo (fosfomycin) for Injection". Dublin....
[4] Nabriva Therapeutics plc. (8/19/19). "Press Release: Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta (lefamulin) to Treat Community-Acquired Bacteria Pneumonia (CABP)". Dublin....
[5] Nabriva Therapeutics plc. (8/16/19). "Press Release: Nabriva Therapeutics Provides Update on the Planned Resubmission of the New Drug Application for Intravenous Contepo (fosfomycin) for Injection". Dublin....
[6] Nabriva Therapeutics plc. (2/19/19). "Press Release: Nabriva Therapeutics Announces Acceptance of New Drug Applications by the FDA for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults". Dublin....
[7] Nabriva Therapeutics plc. (12/21/18). "Press Release: Nabriva Therapeutics Announces Closing of up to a $75 million Term Loan". Dublin....
[8] Nabriva Therapeutics plc. (12/20/18). "Press Release: Nabriva Therapeutics Submits New Drug Applications to U.S. Food and Drug Administration for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults". Dublin....
[9] Nabriva Therapeutics plc. (11/20/18). "Press Release: Nabriva Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference". Dublin & King of Prussia, PA....
[10] Nabriva Therapeutics plc. (11/1/18). "Press Release: Nabriva Therapeutics Completes Submission of New Drug Application to U.S. Food and Drug Administration for Intravenous Contepo to Treat Complicated Urinary Tract Infections". Dublin....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]